OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Acute malnutrition raises risk of malaria treatment failure in young children

Children with acute malnutrition across Africa and Asia have a higher risk of treatment failure and malaria reinfection, even after being given the best currently

March 13, 2024

Opinion | Disruption: Problem and Potential

David Nash is founding dean emeritus and the Dr. Raymond C. and Doris N. Grandon Professor of Health Policy at the Jefferson College of Population

August 31, 2023

SPAC Ashington Innovation plans to acquire dormant biotech Celixir and lead heart failure program for $172M

London-based SPAC Ashington Innovation is planning to acquire dormant, UK-based biotech Celixir for $172 million (£135 million) in an all-share transaction, taking over its lead

August 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.